Zvirwere zveautoimmune, izvo zviri zvemhando dzakasiyana uye zvakanyanya kuramba uye zvakakomba zvirwere, ndeimwe yenzira dzakakosha dzekugadzirwa kwemishonga ikozvino.JAK-STAT ndeimwe yeashoma immunomodulatory nzira dzakaratidzwa, kunyanya JAK inhibitors.Mishonga yakawanda,zvakadai se tofacitinib, zvakatengeswa pasi rose.

Chinangwa cheJAK chakagadzirwa kweasingasviki makore makumi maviri, asi parizvino marudzi angangosvika manomwe akatenderwa kushambadzira.Zviratidzo zvinonyanya kuve nemamota uye zvirwere zvinodzivirira muviri, uye zvimwe zvakanatswa zviratidzo zvakanyanya kunyanya bone marrow fibrosis uye rheumatoid arthritis.Izvi zvinotevera zvinotarisa kune yekutanga JAK inhibitor (tofacitinib) yekurapa rheumatoid arthritis.

Tofacitinib ndeyemuromo diki molecule JAK inhibitor yakagadzirwa naPfizer.Iyo ine yakanaka JAK selectivity.Muna Mbudzi 2012, US FDA yakabvumira tofacitinib citrate yekurapa methotrexate isina kukwana kana kusashivirira mhinduro pakurapwa.Ichi chigadzirwa ndicho chekutanga JAK inhibitor chakabvumidzwa neFDA pakurapa rheumatoid arthritis.Parizvino, kuwedzera kune zvakabvumidzwa zviratidzo, tofacitinib iri kuongororwawo kushanda kwayo muankylosing spondylitis, atopic dermatitis, keratoconjunctivitis sicca uye chirwere cheCrohn.Panyaya yekutengeswa kwepasirese, kutengesa kwepagore kwe tofacitinib muna 2017 kwaidarika bhiriyoni imwe chete yemadhora, uye kutengesa kwepagore muna 2019 kwasvika US$2.242 bhiriyoni.

Nzira dzakasiyana dzekugadzira dzichava nemhedzisiro yakakura pagoho uye mhando yemaAPI.Yedu synthesis ye tofacitinib citrate inodzivirira nzira ine patent.Iyo nzira yekugadzira inoda yakaderera mutengo wezvinhu, goho rakakwira, tsvina imwe chete uye kuchena kunogona kudzorwa mukati mehumwe hunoenderana, kana inogona kugadzirwa nevatengi.Izvi zvinoita kuti tive nemukana uri pachena pamusika.Parizvino huwandu hwedu hunogona kuita 50kg pamwedzi, uye tofacitinib citrate yatotengeswa kuUSA, Mexico, Franch, Bangladesh, nezvimwe.